Module
Hepatitis Journal Options – Volume 3, Issue 2
Source: Journal Options
Hepatitis Journal Options – Volume 3, Issue 2
Program Directors: Raymond T. Chung, MD, Robert G. Gish, MD, Stephen A. Harrison, MD, LTC, MC
  
- Jasmohan Bajaj, MD, MSc
- Wissam Bleibel, MD
- Steven Flamm, MD
|
  
- Ira M. Jacobson, MD
- Daryl T-Y Lau, MD, MSc, MPH
- Kevin Mullen, MD
|
  
- David R. Nelson, MD
- Nancy Reau, MD
- Richard K. Sterling, MD, MSc, FACP, FACG
|
 |
|
Learning Objectives
Upon completion of this activity, participants should be able to:
- Recall data on the efficacy of telaprevir in combination with peginterferon/ribavirin in treatment-naive, genotype 1 patients
- Discuss the efficacy and safety of tenofovir vs adefovir for the treatment of HBeAg-positive and HBeAg-negative chronic hepatitis B patients
- Describe the results of long-term maintenance peginterferon alfa-2a therapy in HCV-infected patients with previous nonresponse
- Summarize the efficacy of rifaximin for the treatment of hepatic encephalopathy
|
Disclaimer:
The materials published on the Clinical Care Options Web site reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the CME provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
|
Jointly sponsored by Postgraduate Institute for Medicine and Clinical Care Options, LLC.
Contact Info
Educational grants provided by:
Educational grants support only the CME-certified components of this program.
|
|